Bristol-Myers Squibb Co at JPMorgan Healthcare Conference Transcript
Good morning, everybody. I'm Chris Schott from J.P. Morgan, and it's my pleasure to be introducing Bristol to kick off the 38th Annual J.P. Morgan Healthcare Conference. From the company, we have Giovanni Caforio, the company's Chairman and CEO.
Bristol's announced acquisition of Celgene was clearly the talk at the conference last year. With the deal now closed, very much looking forward to Giovanni's comments on the new company.
With that, turn it over to Giovanni.
Thank you, Chris. Good morning, everyone. It's a pleasure to be here. I do remember being here a year ago when we had just announced the acquisition of Celgene. I am actually really proud of what has happened in 2019 and how well we are positioned as a company as we start 2020.
So you will remember that -- I'm sorry, can you go back one? Thank you. You remember that last year, I discussed the value of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
